Orifarm targets €3 billion in revenue by 2031 with Europe-wide generics push

Orifarm unveiled a five-year strategy called Fit to Scale to expand its prescription medicines business beyond the Nordics and into more European markets. The company aims to double EBITDA to €300 million and lift revenue above €3 billion by 2031 as it steps up niche generics, parallel imports and consumer healthcare.

Why it matters: - Orifarm is aiming to become a larger European pharmaceutical platform at a time when healthcare systems face budget pressure, supply strain and rising demand for affordable medicines. - The strategy could broaden access to niche generics and other lower-cost medicines across more markets. - Orifarm also set a longer-term target of €1 billion in annual generics sales by 2036.

What happened: - Orifarm launched Fit to Scale, a five-year strategy running through 2031. - The company said it will expand its prescription medicines business from a Nordic base to a broader European platform. - Orifarm targets more than €3 billion in revenue and €300 million in EBITDA by 2031. - The strategy also follows the divestment of Vitamins, Minerals and Supplements earlier this year.

The details: - Orifarm laid out four priorities: accelerate prescription medicines, strengthen its position in parallel-imported medicines, focus consumer healthcare investment on leading brands, and build a scalable operating model. - The prescription medicines plan centers on niche generics, with more launches, faster product introductions and expansion into new markets. - Orifarm said it wants to strengthen its position as the European leader in parallel-imported medicines by improving speed and efficiency and entering new markets. - The consumer healthcare business will focus on well-known brands. - Orifarm said the operating model is designed to support growth from 2027 through 2031 and beyond. - The company said it will continue pursuing targeted acquisitions to support growth across its platforms. - Orifarm said it has 2,300 employees across 16 markets and annual turnover of €2 billion.

Between the lines: - The strategy signals a sharper focus on pharmaceuticals after the earlier sale of Vitamins, Minerals and Supplements. - Orifarm is betting that smaller, underserved generics segments can support growth because larger players often overlook markets that are too small. - The company is using its distribution reach, launch execution and supply capabilities as the basis for expansion across Europe. - Management is framing the strategy as both a growth plan and a scale-up of Orifarm's role in European medicine supply.

What's next: - Orifarm plans to double earnings and the number of product launches in its prescription medicines business between 2027 and 2031. - The company will keep building out its niche generics platform across selected small-molecule therapeutic areas. - Execution now becomes the focus as Orifarm looks to turn the strategy into market expansion and higher sales. - The company said the new plan will be supported by its existing workforce and continued acquisition activity.

The bottom line: - Orifarm is making its biggest push yet beyond the Nordics, with generics at the center of a plan to more than grow revenue, earnings and market reach by 2031.